Format

Send to:

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2013 Apr 15;23(8):2281-7. doi: 10.1016/j.bmcl.2013.02.070. Epub 2013 Feb 26.

HCV versus HIV drug discovery: Déjà vu all over again?

Author information

  • 1Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA. will.watkins@gilead.com

Abstract

Efforts to address HIV infection have been highly successful, enabling chronic suppression of viral replication with once-daily regimens. More recent research into HCV therapeutics have also resulted in very promising clinical candidates. This Digest explores similarities and differences in the two fields and compares the chronology of drug discovery relative to the availability of enabling tools, and concludes that safe and convenient, once-daily regimens are likely to reach approval much more rapidly for HCV than was the case for HIV.

Copyright © 2013 Elsevier Ltd. All rights reserved.

PMID:
23489621
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk